ProShare Advisors
KZR

ProShare Advisors’s Kezar Life Sciences KZR Stock Holding History

ProShare Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,282
Closed -$11.6K – 1928
2024
Q1 		$11.6K Buy
1,282
+101
+9% +$920 ﹤0.01% 1993
2023
Q4 		$11.2K Sell
1,181
-221
-16% -$1.94K ﹤0.01% 1941
2023
Q3 		$16.7K Buy
1,402
+5
+0.4% +$89 ﹤0.01% 1795
2023
Q2 		$34.2K Buy
1,397
+303
+28% +$7.89K ﹤0.01% 1806
2023
Q1 		$34.2K Sell
1,094
-149
-12% -$8.62K ﹤0.01% 1706
2022
Q4 		$87.5K Buy
1,243
+88
+8% +$6.53K ﹤0.01% 1673
2022
Q3 		$100K Buy
+1,155
New +$112K ﹤0.01% 1559
2022
Q2 		– Sell
-1,219
Closed -$204K – 1970
2022
Q1 		$204K Sell
1,219
-237
-16% -$34K ﹤0.01% 1874
2021
Q4 		$243K Sell
1,456
-12
-0.8% -$1.35K ﹤0.01% 1909
2021
Q3 		$127K Sell
1,468
-284
-16% -$18.8K ﹤0.01% 1875
2021
Q2 		$95K Buy
1,752
+275
+19% +$15.6K ﹤0.01% 2298
2021
Q1 		$88K Buy
1,477
+69
+5% +$4.03K ﹤0.01% 2180
2020
Q4 		$73K Buy
+1,408
New +$78.3K ﹤0.01% 2019

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

ProShare Advisors's KZR Position: Q2 2024 in Review

ProShare Advisors sold out of Kezar Life Sciences (KZR) in Q2 2024, closing a stake of 1,282 shares — an estimated $11.6K sold.

ProShare Advisors first reported a position in KZR in Q4 2020 and held it in 13 quarters. The position peaked at $243K in Q4 2021. 81 funds tracked by Wall St. Rank hold KZR as of Q2 2024.

  • ProShare Advisors reported no remaining Kezar Life Sciences position as of Q2 2024 after selling out during the quarter.
  • ProShare Advisors sold 1,282 Kezar Life Sciences shares in Q2 2024, an estimated $11.6K.
  • ProShare Advisors first reported a position in Kezar Life Sciences in Q4 2020 and held it in 13 quarters.
  • ProShare Advisors's Kezar Life Sciences position peaked at $243K in Q4 2021.
  • 81 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2024.

Based on ProShare Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.